Femasys Inc. has received approval from Health Canada for its FemCath intrauterine catheter, which is the first device to allow selective evaluation of fallopian tubes with contrast in the country. The product works together with Femasys' FemVue ultrasound-based diagnostic test as part of an infertility assessment before any therapeutic options can be considered, such as artificial insemination or permanent birth control. Kathy Lee-Sepsick, founder and CEO of Femasys Inc., said that blocked fallopian tubes are a silent factor affecting one out of three infertile women and it was critical to assess each tube's viability using both FemCath alongside FemVue.
Keywords: Femasys Inc., FemCath, intrauterine catheter, Canada approval, selective evaluation
The company's mission is to bring much-needed technologies to women’s healthcare and build out its novel commercial suite of products. Their other biomedical solutions in development include FemaSeed and FemBloc®, which use the same balloon technology platform as the approved product but are not yet cleared by FDA in the United States.
This new medical device helps doctors identify potential issues with a woman's reproductive system early on so they can address them more effectively. By utilizing this non-invasive tool during infertility evaluations prior